MON-186 Retrospective study of ATLG/ Anti-T-lymphocyte Immune Globulin (Grafalon) vs Basiliximab (Simulect) as an induction agent for Kidney transplantation – A single centre experience

摘要

The optimal renal replacement therapy is kidney transplantation because it improves quality of life, prolongs survival, and is cost-effective. Malignancy became the second leading cause of death in kidney allograft recipients. The aim of this study was to the prevalence of malignancy in patients with end-stage renal disease on the kidney transplantation waiting list and in kidney allograft recipients.